New drug combo aims to tackle Hard-to-Treat myeloma
NCT ID NCT07032714
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests two drugs—mezigdomide (a pill) and talquetamab (an injection)—in people with multiple myeloma that has come back or stopped responding to prior treatments. The main goal is to find a safe dose and schedule. About 25 participants will receive the drugs in different sequences to see how well they tolerate them and whether the cancer responds.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mezigdomide and talquetamab
- What this could lead to
- If this works, it could point toward a new treatment option for people with multiple myeloma that has stopped responding to other therapies.
- What could go wrong
- This is a very early (Phase 1) trial with only 25 participants, so it is primarily testing safety and dosing. The drugs may not work well or could cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beth Israel Deaconess Medical Center
NOT_YET_RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Dana-Farber Cancer Institute
NOT_YET_RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for tough myeloma: early trial of BP2202 begins
- Can a Pre-Dose prevent a dangerous reaction in multiple myeloma treatment?
- New hope for myeloma patients: epunamin combo under study
- New combo therapy aims to tackle Hard-to-Treat myeloma
- New drug duo aims to tackle Hard-to-Treat myeloma
- New combo attack on hard-to-treat myeloma enters human testing